Features
Indication prioritization with scored shortlists
Target and modality assessment (druggability, tractability, FTO)
Biomarker and patient selection from genomic/proteomic evidence
Clinical trial design (adaptive design, endpoint strategy, sample size)
Competitive intelligence synthesis
Regulatory gap analysis (IND, safety summaries)
MoA elucidation and target ID
Lead optimization and CMC support
TPP and valuation summaries
Reproducible code and validation protocols
No training on customer data
Supports any therapeutic area and modality
Discovery through commercialization support
Multimodal target discovery with PandaOmics
De novo small molecule design with Chemistry42
Antibody and protein engineering with Generative Biologics
Clinical trial outcome prediction with inClinico
Generative scientific reasoning with Science42:DORA
Large Language Models of Life (LLLMs) for biological sequences
NLP-based literature mining with Nach01
PreciousGPT for longevity and aging research
Automated hit-to-lead optimization
IND-enabling study support
Multi-target pipeline management
AI-driven biomarker identification
Target-to-hit in as little as 18 months
